Our main finding is the functional divergence of SAFA-derived peptides in controlling multiple key cellular processes in normal vs. cancer cells which suggests the potential for SAFA-based treatments via these novel therapeutic molecules. The gene discussed is HNRNPU; the disease is cancer.